Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Virus disease Stories

2012-08-20 02:31:44

CHILLY-MAZARIN, France, August 20, 2012 /PRNewswire/ -- InGen BioSciences, specialized in the development and commercialization of mono and multiparametric in vitro diagnostic tests announced exclusive partnerships with two key in vitro diagnostic companies, Quidel and Diagnostic Hybrids, for the distribution of their innovative tests on the French market. "These exclusive partnerships will allow InGen BioSciences to answer French biologists' unmet needs for early...

2012-07-19 10:23:04

CAMBRIDGE, Mass., July 19, 2012 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has obtained CE-marking for its fourth automated, high-throughput molecular test designed and developed for the Abbott m2000 System. The IMDx HSV-1/2 for Abbott m2000 detects Herpes Simplex Virus (HSV) viral DNA and differentiates HSV-1 and HSV-2 in male and female genital or oral lesions and cerebral spinal fluid (CSF). (Logo: http://photos.prnewswire.com/prnh/20120306/NE63745LOGO ) HSV is the...

2011-12-16 07:00:00

PRINCETON, N.J., Dec. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938. There are 235 individuals with hepatitis C virus (HCV) in the study who are receiving treatment with PSI-938 alone or in combination with PSI-7977 or PSI-7977 and ribavirin. During routine safety monitoring, the company...

2011-11-01 05:00:00

PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy. "After recent discussions with Health Authorities, we are excited to be initiating the first of...

2011-09-15 12:18:57

Response-guided treatment with drug telaprevir can be shortened to 6 months for many, says research published in New England Journal of Medicine Treatment with a telaprevir-based combination regimen for hepatitis C — heretofore a chronic, destructive and difficult to manage disease — effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine. Telaprevir, a drug approved for use...

2011-09-15 11:35:54

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication–a telaprevir-based regimen that is commonly used to treat the illness–for 24 weeks were cured. Usually, the treatment is administered for 48 weeks, and these results show that extended treatment is unnecessary, possibly changing the standard of care for hepatitis C patients....

2011-09-14 11:15:38

Press release from PLoS Medicine In this week's PLoS Medicine, David Booth of the University of Sydney, Australia and colleagues show that genotyping hepatitis C patients for the IL28B, HLA-C and KIR genes substantially improves doctors' ability to predict whether or not patients will respond to antiviral treatment. The results of the study suggest that an interaction between IL28B, HLA-C and KIRs provides a mechanism for hepatitis C viral control and highlight new insights into how the...

2011-09-14 05:29:43

(Ivanhoe Newswire) — Genotyping hepatitis C patients significantly improves doctors´ ability to predict whether or not patients will respond to antiviral treatment. The results of the study suggest that an interaction between IL28B, HLA-C and KIRs genes provides a mechanism for hepatitis C viral control and highlight new insights into how the drug combination of pegylated interferon alpha and ribavirin clears hepatitis C virus infections, findings that may lead to improved...

2011-06-08 21:41:55

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack. The findings, which support a long-held view on how MS may develop, are published in The Journal of Infectious Diseases and now available online (http://jid.oxfordjournals.org/content/early/2011/06/07/infdis.jir239.abstract). MS is an autoimmune disease that affects the brain and spinal cord, leading to inflammation...

2011-05-13 16:15:00

SILVER SPRING, Md., May 13, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment. Victrelis is approved for use in combination with peginterferon alfa and ribavirin. (Logo:...


Latest Virus disease Reference Libraries

45_54436b68455b543bc3458afb0a44fb27
2011-02-17 17:26:28

Mumps virus causes mumps which is a common childhood disease characterized by swelling of the parotid glands and other epithelial tissues causing high morbidity in some cases deafness. Infection is currently restricted to humans while the virus is transmitted by direct contact, droplet spread, or via contaminated objects. It is a vaccine preventable disease although significant outbreaks have occurred in recent years in regions with high levels of vaccination. The virus belongs to the genus...

More Articles (1 articles) »